Glp-1-based strategies: A physiological analysis of differential mode of action

Physiology

Volumn 29, Issue 2, 2014, Pages 108-121

  Burcelin, Rémy ^a   Gourdy, Pierre ^a,b   Dalle, Stéphane ^c  

^a University Hospital of Toulouse   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; INCRETIN;

ANIMAL; BRAIN; HUMAN; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS;

ANIMALS; BRAIN; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; RECEPTORS, GLUCAGON;

EID: 84900796570     PISSN: 15489213     EISSN: 15489221     Source Type: Journal    
DOI: 10.1152/physiol.00009.2013     Document Type: Review

References (177)

1. Abbas T, Faivre E, Holscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between Type 2 diabetes and Alzheimer's disease. Behav Brain Res 205: 265-271, 2009.
2. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, Ghatei MA, Bloom SR. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044: 127-131, 2005.
3. Adachi A. Electrophysilogical study of hepatic vagal projection to the medulla. Neurosci Lett 24: 19-23, 1981.
4. Adachi A, Shimizu N, Oomura Y, Kobashi M. Convergence of hepatoportal glucose-sensitive afferent signals to glucose-sensitive units within the nucleus of the solitary tract. Neu-rosci Lett 46: 215-218, 1984.
5. Ahren B. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. Am J Physiol Regul Integr Comp Physiol 286: R269-R272, 2004.
6. Ahren B, Schweizer A, Dejager S, Dunning BE, Nilsson PM, Persson M, Foley JE. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with Type 2 diabetes. J Clin Endocrinol Metab 94: 1236-1243, 2009.
7. Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 153: 647-658, 2012.
8. Alvarez E, Martinez MD, Roncero I, Chowen JA, Garcia-Cuartero B, Gispert JD, Sanz C, Vazquez P, Maldonado A, de Caceres J, Desco M, Pozo MA, Blazquez E. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 92: 798-806, 2005.
9. Alvarez E, Roncero I, Chowen JA, Thorens B, Blazquez E. Expression of the glucagon-like peptide-1 receptor gene in rat brain. J Neurochem 66: 920-927, 1996.
10. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 92: 1249-1255, 2007.
11. Batterham RL, Heffron H, Kapoor S, Chivers JE, Chandarana K, Herzog H, Le Roux CW, Thomas EL, Bell JD, Withers DJ. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 4: 223-233, 2006.
12. Becker RHA, Ruus P, YH Liu, Kapitza C. Restoration of insulin release with lixisenatide in patients with Type 2 diabetes. Diabetologia 53: S339 2010.
13. Beinborn M, Worrall CI, McBride EW, Kopin AS. A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness. Regul Pept 130: 1-6, 2005.
14. Blazquez E, Alvarez E, Navarro M, Roncero I, Rodriguez-Fonseca F, Chowen JA, Zueco JA. Glucagon-like peptide-1 (7-36) amide as a novel neuropeptide. Mol Neurobiol 18: 157-173, 1998.
15. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54: 146-151, 2005.
16. Burcelin R. The gut-brain axis: a major glucoregu-latory player. Diabet Metab 36, Suppl 3: S54-S58, 2010.
17. Burcelin R, Da Costa A, Drucker D, Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glu-cagon-like peptide-1 receptor. Diabetes 50: 1720-1728, 2001.
18. Burcelin R, Dolci W, Thorens B. Portal glucose infusion in the mouse induces hypoglycemia. Evidence that the hepatoportal glucose sensor stimulates glucose utilization. Diabetes 49: 1635-1642, 2000.
19. Burcelin R, Knauf C, Cani PD. Pancreatic alpha-cell dysfunction in diabetes. Diabetes Metab 34, Suppl 2: S49-S55, 2008.
20. Cabou C, Burcelin R. GLP-1, the gut-brain, and brain-periphery axes. Rev Diabet Stud 8: 418-431, 2012.
21. Cabou C, Cani PD, Campistron G, Knauf C, Ma-thieu C, Sartori C, Amar J, Scherrer U, Burcelin R. Central insulin regulates heart rate and arterial blood flow: an endothelial nitric oxide synthase-dependent mechanism altered during diabetes. Diabetes 56: 2872-2877, 2007.
22. Cherrington AD, Chiasson JL, Liljenquist JE, Jennings AS, Keller U, Lacy WW. The role of insulin and glucagon in the regulation of basal glucose production in the postabsorptive dog. J Clin Invest 58: 1407-1418, 1976.
23. Christensen M, Knop FK. Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide? Curr Diabetes Rep 10: 124-132, 2010.
24. Chrysant SG, Chrysant GS. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am J Car-diol 109: 1681-1685, 2012.
25. Creutzfeldt W. The incretin concept today. Dia-betologia 16: 75-85, 1979.
26. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I (7-36) amide in type I diabetic patients. Diabetes Care 19: 580-586, 1996.
27. Dardevet D, Moore MC, Neal D, DiCostanzo CA, Snead W, Cherrington AD. Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region. Am J Physiol Endocrinol Metab 287: E75-E81, 2004.
28. Davidson MB. Role of glucose transport and GLUT4 transporter protein in Type 2 diabetes mellitus. J Clin Endocrinol Metab 77: 25-26, 1993.
29. Deacon C, Nauck M, Meier J, Hücking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in Type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85: 3575-3581, 2000.
30. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res 36: 761-765, 2004.
31. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80: 952-957, 1995.
32. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L Effects of ex-enatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 24: 2943-2952, 2008.
33. Derosa G, Maffioli P. GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. Curr Clin Pharmacol 7: 214-228, 2012.
34. Dillon J, Lu M, Bowen S, Homan L The recombinant rat glucagon-like peptide-1 receptor, expressed in an alpha-cell line, is coupled to adenylyl cyclase activation and intracellular calcium release. Exp Clin Endocrinol Diabetes 113: 182-189, 2005.
35. Ding WG, Renstrom E, Rorsman P, Buschard K, Gromada J. Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca -induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. Diabetes 46: 792-800, 1997.
36. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and di-peptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705, 2006.
37. Duez H, Smith AC, Xiao C, Giacca A, Szeto L, Drucker DJ, Lewis GF. Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice. Endocrinology 150: 56-62, 2009.
38. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsi-mons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 9: 1173-1179, 2003.
39. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspec-tum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267: 7402-7405, 1992.
40. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101: 515-520, 1998.
41. Flock G, Baggio LL, Longuet C, Drucker DJ. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 56: 3006-3013, 2007.
42. Fujita Y, Wideman RD, Asadi A, Yang GK, Baker R, Webber T, Zhang T, Wang R, Ao Z, Warnock GL, Kwok YN, Kieffer TJ. Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion. Gastroenterology 138: 1966-1975, 2010.
43. Fujiwara K, Gotoh K, Chiba S, Masaki T, Katsuragi I, Kakuma T, Yoshimatsu H. Intraportal administration of DPP-IV inhibitor regulates insulin secretion and food intake mediated by the hepatic vagal afferent nerve in rats. J Neurochem 121: 66-76, 2012.
44. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268: 19650-19655, 1993.
45. Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Identification of specific binding sites for glucagon-like peptide-1 on the posterior lobe of the rat pituitary. Neuroendocrinology 62: 130-134, 1995.
46. Goke R, Wagner B, Fehmann HC, Goke B. Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. Res Exp Med (Berl) 193: 97-103, 1993.
47. Gremlich S, Porret A, Hani EH, Cherif D, Vionnet N, Froguel P, Thorens B. Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insuli-notropic polypeptide receptor. Diabetes 44: 1202-1208, 1995.
48. Guan X, Shi X, Li X, Chang B, Wang Y, Li D, Chan L. GLP-2 receptor in POMC neurons suppresses feeding behavior and gastric motility. Am J Physiol Endocrinol Metab 303: E853-E864, 2012.
49. Hamilton A, Patterson S, Porter D, Gault VA, Holscher C. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res 89: 481-489, 2011.
50. Hansen L, Deacon C, Orskov C, Holst JJ. Gluca-gon like peptide-1-(7-36)aminde is transformed to glucagon like peptide-1-(9-36)amide by di-peptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140: 5356-5363, 1999.
51. Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K, Seino Y, Holst JJ, Schuit F, Drucker DJ. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the en-teroinsular axis in transducing the glucoregula-tory actions of DPP-IV inhibitors. Diabetes 53: 1326-1335, 2004.
52. Hare KJ, Vilsboll T, Asmar M, Deacon CF, Knop FK, Holst JJ The glucagonostatic and insulino-tropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 59: 1765-1770, 2010.
53. Hayes MR, Bradley L, Grill HJ. Endogenous hind-brain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. Endocrinology 150: 2654-2659, 2009.
54. Hayes MR, De Jonghe BC, Kanoski SE. Role of the glucagon-like-peptide-1 receptor in the control of energy balance. Physiol Behav 100: 503-510, 2010.
55. Hayes MR, Kanoski SE, Alhadeff AL, Grill HJ. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats. Obesity (Silver Spring) 19: 1342-1349, 2011.
56. Hayes MR, Skibicka KP, Grill HJ. Caudal brains-tem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-pep-tide-1 receptor stimulation. Endocrinology 149: 4059-4068, 2008.
57. He M, Su H, Gao W, Johansson SM, Liu Q, Wu X, Liao J, Young AA, Bartfai T, Wang MW. Reversal of obesity and insulin resistance by a non-pep-tidic glucagon-like peptide-1 receptor agonist in diet-induced obese mice. PLos One 5: e14205, 2010.
58. Heller R, Kieffer T, Habener J. Insulinotropic glu-cagon-like peptide I receptor expression in glu-cagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 46: 785-791, 1997.
59. Heller RS, Kieffer TJ, Habener JF. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 46: 785-791, 1997.
60. Helman A, Marre M, Bobbioni E, Poussier P, Reach G, Assan R. The brain-islet axis: the nervous control of the endocrine pancreas. Diabete Metab 8: 53-64, 1982.
61. Hevener AL, Bergman RN, Donovan CM. Novel glucosensor for hypoglycemic detection localized to the portal vein. Diabetes 46: 1521-1525, 1997.
62. Himeno T, Kamiya H, Naruse K, Harada N, Ozaki N, Seino Y, Shibata T, Kondo M, Kato J, Okawa T, Fukami A, Hamada Y, Inagaki N, Drucker DJ, Oiso Y, Nakamura J. Beneficial effects of exen-din-4 on experimental polyneuropathy in diabetic mice. Diabetes 60: 2397-2406, 2011.
63. Hjollund KR, Deacon CF, Holst JJ. Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs. Diabetologia 54: 2206-2208, 2011.
64. Holst JJ. The physiology of glucagon-like pep-tide 1. Physiol Rev 87: 1409-1439, 2007.
65. Holst JJ, Burcelin R, Nathanson E. Neuroprotec-tive properties of GLP-1: theoretical and practical applications. Curr Med Res Opin 27: 547-558, 2011.
66. Huisamen B, Genis A, Marais E, Lochner A. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardio-vasc Drugs Ther 25: 13-20, 2011.
67. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Vil-lanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol Gastrointest Liver Physiol 273: G920-G927, 1997.
68. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyper-glycemia in Type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35: 1364-1379, 2012.
69. Ionut V, Hucking K, Liberty IF, Bergman RN. Syn-ergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. Diabeto-logia 48: 967-975, 2005.
70. Ionut V, Liberty IF, Hucking K, Lottati M, Ste-fanovski D, Zheng D, Bergman RN. Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action. Am J Physiol Endocrinol Metab 291: E779-E785, 2006.
71. Irwin N, Flatt PR. Therapeutic potential for GIP receptor agonists and antagonists. Best practice and research. Clin Endocrinol Metab 23: 499-512, 2009.
72. Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M, Knudsen LB. Liraglutide: shortlived effect on gastric emptying: long lasting effects on body weight. Diabetes Obes Metab 14: 531-538, 2012.
73. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes melli-tus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 11: 3, 2012.
74. Johnson KM, Edgerton DS, Rodewald T, Scott M, Farmer B, Neal D, Cherrington AD. Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels. Am J Physiol Endocrinol Metab 293: E1085-E1091, 2007.
75. Jungermann K, Gardemann A, Beuers U, Balle C, Sannemann J, Beckh K, Hartmann H. Regulation of liver metabolism by the hepatic nerves. Adv Enzyme Regul 26: 63-88, 1987.
76. Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 152: 3103-3112, 2011.
77. Kanoski SE, Rupprecht LE, Fortin SM, De Jonghe BC, Hayes MR. The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglu-tide. Neuropharmacology 62: 1916-1927, 2012.
78. Kedees M, Grigoryan M, Guz Y, Teitelman G. Differential expression of glucagon and gluca-gon-like peptide 1 receptors in mouse pancreatic alpha and beta cells in two models of alpha cell hyperplasia. Mol Cell Endocrinol 13: 69-76, 2009.
79. Khoo EY, Wallis J, Tsintzas K, Macdonald IA, Mansell P. Effects of exenatide on circulating glucose, insulin, glucagon, cortisol and cat-echolamines in healthy volunteers during exercise. Diabetologia 53: 139-143, 2010.
80. Kielgast U, Asmar M, Madsbad S, Holst JJ. Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients. J Clin Endocrinol Metab 95: 2492-2496, 2010.
81. Kilimnik G, Kim A, Steiner DF, Friedman TC, Hara M. Intraislet production of GLP-1 by activation of prohormone convertase 1/3 in pancreatic alpha-cells in mouse models of ss-cell regeneration. Islets 2: 149-155, 2010.
82. Kinzig KP, D'Alessio DA, Seeley RJ. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci 22: 10470-10476, 2002.
83. Kirchner H, Tong J, Tschop MH, Pfluger PT. Ghrelin and PYY in the regulation of energy balance and metabolism: lessons from mouse mutants. Am J Physiol Endocrinol Metab 298: E909-E919, 2010.
84. Knauf C, Cani P, Perrin C, Iglesias M, Maury J, Bernard E, Benhamed F, Grémeaux T, Drucker D, Kahn C, Girard J, Tanti J, Delzenne N, Postic C, Burcelin R. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 115: 3554-3563, 2005.
85. Knauf C, Cani PD, Ait-Belgnaoui A, Benani A, Dray C, Cabou C, Colom A, Uldry M, Rastrelli S, Sabatier E, Godet N, Waget A, Penicaud L, Valet P, Burcelin R. Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 149: 4768-4777, 2008.
86. Knauf C, Cani PD, Kim DH, Iglesias MA, Chabo C, Waget A, Colom A, Rastrelli S, Delzenne NM, Drucker DJ, Seeley RJ, Burcelin R. Role of central nervous system glucagon-like peptide-1 receptors in enteric glucose sensing. Diabetes 57: 2603-2612, 2008.
87. Koda S, Date Y, Murakami N, Shimbara T, Ha-nada T, Toshinai K, Niiji A, Furuya M, Inomata N, Osuye K, Nakazato M. The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology 146: 2369-2375, 2005.
88. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD. Synthetic exendin-4 (ex-enatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88: 3082-3089, 2003.
89. Koole C, Wootten D, Simms J, Valant C, Miller LJ, Christopoulos A, Sexton PM. Polymorphism and ligand dependent changes in human glucagon-like peptide-1 receptor (GLP-1R) function: allo-steric rescue of loss of function mutation. Mol Pharmacol 80: 486-497, 2011.
90. Kreymann B, Ghatei MA, Burnet P, Williams G, Kanse S, Diani AR, Bloom SR. Characterization of glucagon-like peptide-1-(7-36)amide in the hypo-thalamus. Brain Res 502: 325-331, 1989.
91. Kreymann B, Ghatei MA, Domin J, Kanse S, Bloom SR. Developmental patterns of glucagon-like peptide-1-(7-36) amide and peptide-YY in rat pancreas and gut. Endocrinology 129: 1001-1005, 1991.
92. Lamont B, Li Y, Kwan E, Brown T, Gaisano H, Drucker D. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J Clin Invest 122: 388-402, 2011.
93. Lamont BJ, Drucker DJ. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes 57: 190-198, 2008.
94. Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW, Tweedie D, Perry T, Mattson MP, Kapogiannis D, Sambamurti K, Lahiri DK, Greig NH. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J Alzheimers Dis 19: 1205-1219, 2010.
95. Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics): preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 23: 463-477, 2009.
96. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 97: 6874-6879, 2000.
97. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 90: 4888-4894, 2005.
98. McIntyre N, Holdsworth C, Turner D. Intestinal factors in the control of insulin secretion. J Clin Endocrinol Metab 25: 1317-1324, 1965.
99. Meier JJ, Gethmann A, Gotze O, Gallwitz B, Holst JJ, Schmidt WE, Nauck MA. Glucagon-like peptide 1 abolishes the postprandial rise in tri-glyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetolo-gia 49: 452-458, 2006.
100. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory poly-peptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214: 829-835, 1993.
101. Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like pep-tide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403: 261-280, 1999.
102. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsu-kiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8: 738-742, 2002.
103. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, Tsuda K, Hashimoto H, Yamashita T, Jomori T, Tashiro F, Miyazaki J, Seino Y. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 96: 14843-14847, 1999.
104. Monami M, Iacomelli I, Marchionni N, Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 20: 224-235, 2009.
105. Moore MC, Satake S, Baranowski B, Hsieh PS, Neal DW, Cherrington AD. Effect of hepatic den-ervation on peripheral insulin sensitivity in conscious dogs. Am J Physiol Endocrinol Metab 282: E286-E296, 2002.
106. Nadeau DA. Review of liraglutide versus sitaglip-tin for patients with uncontrolled type 2 diabetes: more effective HbA 1c reduction with subcutaneous GLP-1 receptor agonist versus an oral DPP-4 inhibitor. Postgrad Med 122: 185-188, 2010.
107. Nagell CF, Wettergren A, Orskov C, Holst JJ. Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs. Scand J Gastroenterol 41: 667-672, 2006.
108. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol Endocrinol Metab 271: E808-E813, 1996.
109. Nakade Y, Tsukamoto K, Pappas TN, Takahashi T. Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats. Brain Res 1111: 117-121, 2006.
110. Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S, Kigoshi T, Nakayama K, Uchida K. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 110: 36-43, 2004.
111. Nakashima K, Shimoda M, Hamamoto S, Tatsumi F, Hirukawa H, Tawaramoto K, Kanda Y, Kaku K. Self-inducible secretion of glucagon-like pep-tide-1 (GLP-1) that allows MIN6 cells to maintain insulin secretion and insure cell survival. Mol Cell Endocrinol 349: 281-288, 2012.
112. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1[7-36 amide] but not of synthetic human gastric inhibitory poly-peptide in patients with type-2 diabetes mellitus. J Clin Invest 91: 301-307, 1993.
113. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63: 492-498, 1986.
114. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 60: 1561-1565, 2011.
115. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273: E981-E988, 1997.
116. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 54: 10-18, 2011.
117. Nie Y, Nakashima M, Brubaker PL, Li QL, Perfetti R, Jansen E, Zambre Y, Pipeleers D, Friedman TC. Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats. J Clin Invest 105: 955-965, 2000.
118. Niijima A. Afferent impulse discharges from glu-coreceptors in the liver of the guinea pig. Ann NY Acad Sci 157: 690-700, 1969.
119. Niijima A. Glucose-sensitive afferent nerve fibers in the liver and their role in food intake and blood glucose regulation. J Auton Nerv Syst 9: 207-220, 1983.
120. Niijima A. Visceral afferents and metabolic function. Diabetologia 20: 325-330, 1981.
121. Nishizawa M, Moore MC, Shiota M, Gustavson SM, Snead WL, Neal DW, Cherrington AD. Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs. Am J Physiol En-docrinol Metab 284: E1027-E1036, 2003.
122. Nishizawa M, Nakabayashi H, Kawai K, Ito T, Kawakami S, Nakagawa A, Niijima A, Uchida K. The hepatic vagal reception of intraportal GLP-1 is via receptor different from the pancreatic GLP-1 receptor. J Auton Nerv Syst 80: 14-21, 2000.
123. Nishizawa M, Nakabayashi H, Uchida K, Naka-gawa A, Niijima A. The hepatic vagal nerve is receptive to incretin hormone glucagon-like pep-tide-1, but not to glucose-dependent insulino-tropic polypeptide, in the portal vein. J Auton Nerv Syst 61: 149-154, 1996.
124. Orskov C, Poulsen SS, Moller M, Holst JJ. Gluca-gon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 45: 832-835, 1996.
125. Pannacciulli P, Le DS, Salbe A, Chen K, Reiman EM, Tataranni P, Krakoff J. Postprandial gluca-gon-like peptide-1 (GLP-1) response is positively associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in humans. Neuroimage 86: 573-579, 2007.
126. Parker H, Wallis K, le Roux C, Wong K, Reimann F, Gribble F. Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br J Pharmacol 165: 414-423, 2012.
127. Paschetta E, Hvalryg M, Musso G. Glucose-dependent insulinotropic polypeptide: from patho-physiology to therapeutic opportunities in obesity-associated disorders. Obes Rev 12: 813-828, 2011.
128. Perry T, Greig NH. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr Alzheimer Res 2: 377-385, 2005.
129. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302: 881-888, 2002.
130. Perry TA, Greig NH. A new Alzheimer's disease interventive strategy: GLP-1. Curr Drug Targets 5: 565-571, 2004.
131. Pinelli NR, Hurren KM. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Ann Pharma-cother 45: 850-860, 2011.
132. Pinkney J, Fox T, Ranganath L. Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide. Therap Clin Risk Management 6: 401-411, 2010.
133. Pratley RE, Nauck M, Bailey T, Montanya E, Cud-dihy R, Filetti S, Thomsen AB, Sondergaard RE, Davies M. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375: 1447-1456, 2010.
134. Preitner F, Ibberson M, Franklin I, Binnert C, Pende M, Gjinovci A, Hansotia T, Drucker DJ, Wollheim C, Burcelin R, Thorens B. Gluco-incre-tins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest 113: 635-645, 2004.
135. Reimann F, Gribble FM. Glucose-sensing in glu-cagon-like peptide-1-secreting cells. Diabetes 51: 2757-2763, 2002.
136. Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM. Glucose sensing in L cells: a primary cell study. Cell Metab 8: 532-539, 2008.
137. Renner E, Puskas N, Dobolyi A, Palkovits M. Glu-cagon-like peptide-1 of brainstem origin activates dorsomedial hypothalamic neurons in satiated rats. Peptides 35: 14-22, 2012.
138. Rinaman L Afunctional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia. Am J Physiol Regul Integr Comp Physiol 277: R1537-R1540, 1999.
139. Rinaman L Interoceptive stress activates glucagon -like peptide-1 neurons that project to the hypothalamus. Am J Physiol Regul Integr Comp Physiol 277: R582-R590, 1999.
140. Said G. Diabetic neuropathy: a review. Nat Clin Pract Neurol 3: 331-340, 2007.
141. Salcedo I, Tweedie D, Li Y, Greig NH. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol 166: 1586-1599, 2012.
142. Santer R, Schneppenheim R, Dombrowski A, Go-tze H, Steinmann B, Schaub J. Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome. Nat Genet 17: 324-326, 1997.
143. Scheepers A, Joost HG, Schurmann A. The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. JPEN J Parenter Enteral Nutr 28: 364-371, 2004.
144. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nature Medicine 2: 1254-1258, 1996.
145. Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M, Sheikh SP. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol Regul Integr Comp Physiol 271: R848-R856, 1996.
146. Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int J Obes Relat Metab Disord 25, Suppl 5: S42-S47, 2001.
147. Tews D, Werner U, Eckel J. Enhanced protection against cytokine- and fatty acid-induced apopto-sis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues. Horm Metab Res 40: 172-180, 2008.
148. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 89: 8641-8645, 1992.
149. Thorens B. Glucagon-like peptide-1 and control of insulin secretion. Diabete Metabolisme 21: 311-318, 1995.
150. Thorens B. Molecular and cellular physiology of GLUT2. Int Rev Cytol 137A: 209-238, 1992.
151. Thorens B, Wu Y, Leahy J, Weir G. The loss or GLUT2 expression by glucose unresponsive β3 cells of db/db mice is reversible and is induced by the diabetic environement. J Clin Invest 90: 77-85, 1992.
152. Toft-Nielsen MB, Madsbad S, Holst JJ. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab 86: 3853-3860, 2001.
153. Tolhurst G, Reimann F, Gribble FM. Intestinal sensing of nutrients. Hand Exp Pharmacol 209: 309-335, 2012.
154. Tornehave D, Kristensen P, Romer J, Knudsen LB, Heller RS. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem 56: 841-851, 2008.
155. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 13: 366-373, 2011.
156. Tseng CC, Boylan MO, Jarboe LA, Usdin TB, Wolfe MM. Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats. Am J Physiol Endocrinol Metab 270: E661-E666, 1996.
157. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72, 1996.
158. Unger RH. Glucagon physiology and pathophys-iology in the light of new advances. Diabetologia 28: 574-578, 1985.
159. Unger RH, Orci L. The role of glucagon in the endogenous hyperglycemia of diabetes mellitus. Ann Rev Med 28: 119-130, 1977.
160. Uttenthal LO, Toledano A, Blazquez E. Autora-diographic localization of receptors for gluca-gon-like peptide-1 (7-36) amide in rat brain. Neuropeptides 21: 143-146, 1992.
161. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fer-nandes TM, Bitner RD, Ellis KS, Woods SC, Seeley RJ, Herman JP, D'Alessio DA. Gluca-gon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148: 4965-4973, 2007.
162. Velho G, Froguel P, Clement K, Pueyo ME, Ra-kotoambinina B, Zouali H, Passa P, Cohen D, Robert JJ. Primary pancreatic beta-cell secretory defect caused by mutations in glucokinase gene in kindreds of maturity onset diabetes of the young. Lancet 340: 444-448, 1992.
163. Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Dunning BE, Foley JE, Rizza RA, Ca-milleri M. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 56: 1475-1480, 2007.
164. Verges B, Bonnard C, Renard E. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes Metab 37: 477-488, 2011.
165. Violante R, Oliveira JH, Yoon KH, Reed VA, Yu MB, Bachmann OP, Ludemann J, Chan JY. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with Type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin. Diabet Med 29: e417-e424, 2012.
166. Waget A, Cabou C, Masseboeuf M, Cattan P, Armanet M, Karaca M, Castel J, Garret C, Payros G, Maida A, Sulpice T, Holst JJ, Drucker DJ, Magnan C, Burcelin R. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 152: 3018-3029, 2011.
167. Weir GC, Mojsov S, Hendrick GK, Habener JF. Glucagonlike peptide I (7-37) actions on endocrine pancreas. Diabetes 38: 338-342, 1989.
168. Wettergren A, Wojdemann M, Meisner S, Stadil F, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 40: 597-601, 1997.
169. Whalley NM, Pritchard LE, Smith DM, White A. Processing of proglucagon to GLP-1 in pancreatic alpha-cells: is this a paracrine mechanism enabling GLP-1 to act on beta-cells? J Endocrinol 211: 99-106, 2011.
170. Williams DL, Baskin DG, Schwartz MW. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 55: 3387-3393, 2006.
171. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (nonin-sulin-dependent) diabetic patients. J Clin Endo-crinol Metab 81: 327-332, 1996.
172. Winer DA, Winer S, Shen L, Wadia PP, Yantha J, Paltser G, Tsui H, Wu P, Davidson MG, Alonso MN, Leong HX, Glassford A, Caimol M, Kenkel JA, Tedder TF, McLaughlin T, Miklos DB, Dosch HM, Engleman EG. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med 17: 610-617, 2011.
173. Wysham C, Bergenstal R, Malloy J, Yan P, Walsh B, Malone J, Taylor K. DURATION-2: efficacy and safety of switching from maximum daily sitaglip-tin or pioglitazone to once-weekly exenatide. Diabet Med 28: 705-714, 2011.
174. Xu G, Kaneto H, Laybutt DR, Duvivier-Kali VF, Trivedi N, Suzuma K, King GL, Weir GC, Bonner-Weir S. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 56: 1551-1558, 2007.
175. Yabe D, Seino Y. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and beta cell preservation. Prog Bio-phys Mol Biol 107: 248-256, 2011.
176. Yasuda K, Inagaki N, Yamada Y, Kubota A, Seino S, Seino Y. Hamster gastric inhibitory polypep-tide receptor expressed in pancreatic islets and clonal insulin-secreting cells: its structure and functional properties. Biochem Biophys Res Commun 205: 1556-1562, 1994.
177. Yoshimoto S, Hirota M, Ohboshi C, Shima K. Identification of glucagon-like peptide-1(7-36) amide in rat brain. Ann Clin Biochem 26: 169-171, 1989.